#ESMO26 Dr. David Sommerhalder presents OS from M21-404: telisotuzumab adizutecan (Temab-A), a c-MET directed ADC with a topo-1 payload. mPFS 6.8m OS 13.8m in EGFR wild type. mPFS

Stephen V Liu, MD· @StephenVLiu · X·2026-10-24 15:45· 22 小时前评分70

正文 · 原文

#ESMO26 Dr. David Sommerhalder presents OS from M21-404: telisotuzumab adizutecan (Temab-A), a c-MET directed ADC with a topo-1 payload. mPFS 6.8m OS 13.8m in EGFR wild type. mPFS 10.9m OS 16.2m in EGFR mutant. cMET expression predicts outcomes in EGFRwt, not so in EGFRmt.

103 浏览 · 2 赞 · 0 转发 · 0 回复

会议摘要

2658RO按 Rapid oral 1: NSCLC, metastatic 对上

Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study

https://esmocongress.esmo.org

791RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上

Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study

https://esmocongress.esmo.org

来源：Stephen V Liu, MD · x.com